NCT01398280

Effects of Aminocaproic Acid (ACA) on Rosacea-specific Inflammation

A Single Site Evaluation of the Effect of Topical Application of Aminocaproic Acid (ACA) to Inhibit Kallikrein 5 Serine Protease Activity and Production of LL-37 Cathelicidin Peptide, Biochemical Markers of Rosacea-specific Inflammation.

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: University of California, San Diego · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effect of topical aminocaproic acid on the immune system by assessing the levels of antimicrobial peptides in the skin of patients with rosacea. It is hypothesized that aminocaproic acid applied topically will alter the body's immune system in patients with rosacea by inhibiting activation of antimicrobial peptides.

Conditions

• Rosacea

Interventions

Type	Name	Description
DRUG	Topical aminocaproic acid (ACA) mixed with Vanicream	25% Aminocaproic acid cream twice daily for up to 12 weeks.
DRUG	Vehicle cream	Vehicle cream moisturizer twice daily for up to 12 weeks

Timeline

• Start date: 2011-07-01
• Primary completion: 2012-12-01
• Completion: 2012-12-01
• First posted: 2011-07-20
• Last updated: 2019-09-13
• Results posted: 2019-09-13

Locations

1 site across 1 country: United States